Key Highlights
- (Viatris) for a total consideration of $815 million, of which $400 million will be payable in cash and the rest through a share swap of 61.70 Biocon shares for every 100 Biocon Biologics shares, at ₹405.78 per share.
- The integration of the unit is expected to be completed by 31 March 2026.
- The company had constituted a strategy committee in May 2025 to evaluate a potential merger or public listing for the biologics arm.
- “After careful consideration of key parameters such as strategic alignment, sectoral dynamics, shareholder value creation, and other relevant data, the Committee concluded that full integration of Biocon Biologics Limited with Biocon Limited offers the most efficient and value-accretive path forward,” the company said in a release.
- Biocon's board has also approved raising additional capital, up to ₹4,500 crore through qualified institutional placement (QIP), subject to shareholder approval.
